1:10 Stock Split of Pharma Stock: Record Date Set For March 21; What Investors Should Do Next?

An Indian business called Shukra Pharmaceuticals Limited produces and sells pharmaceutical products. Founded in 1993, the business was once known as Relish Pharmaceuticals Limited. On Friday, the shares of Shukra Pharmaceuticals ended 1.99% lower at Rs 236.40 per share on the BSE with a market cap of Rs 1,035.15 Cr after the company declared record date for 1:10 stock split.

Shukra Pharmaceuticals Stock Split Date

"Pursuant to Regulation 42 of the securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Friday, 21st March,2025 has been fixed as the Record Date to ascertain the eligibility of Shareholders for the purpose of sub-division / split of the Equity Shares of the company such that every 1(one) Equity Share having nominal/face value of Rs. 10/- [Rupees Ten 0nly} each be sub-divided into 10 [Ten) Equity shares having nominal/face value of Rs. 1/- (Rupees one 0nly) each," said Shukra Pharmaceuticals in a stock exchange filing.

Shukra Pharmaceuticals Share Price

On Friday, the shares of Shukra Pharmaceuticals ended at a 2% lower circuit limit at Rs 236.40 per share with a market cap of Rs 1,035.15 Cr. The pharma stock reached a 52-week-high of Rs 271.50 on (05/03/2025) and a 52-week-low of Rs 57.52 on (21/11/2024).

Shukra Pharmaceuticals Share Price Target

"Shukra Pharmaceuticals stock price is bearish on the Daily charts with strong resistance at 246. A Daily close below support of 231 could lead to a target of 207 in the near term," commented A R Ramachandran, Independent Research Analyst.

Disclaimer

The recommendations made above are by market analysts and are not advised by either the author, nor Greynium Information Technologies. The author, nor the brokerage firm nor Greynium would be liable for any losses caused as a result of decisions based on this write-up. Goodreturns.in advises users to consult with certified experts before making any investment decision.